Lenvatinib Therapy

Lenvatinib Therapy is a targeted molecular therapy within the class of multikinase inhibitors, distinguished by its selective inhibition of vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT, employed in the systemic treatment of advanced hepatocellular carcinoma.

786

Publications

48.7K

Citations

5.6K

Authors

1.4K

Institutions

Publications per year

2017–2026

731

Authors

5.6K

  1. MK
    Masatoshi Kudo

    Kindai University, Japan

    61 publications · 12K citations

    39

    h-index

  2. CE
    Corina E. Dutcus

    Eisai (United States), United States

    55 publications · 14.6K citations

    34

    h-index

  3. AH
    Atsushi Hiraoka

    Ehime Prefectural Central Hospital, Japan

    38 publications · 2K citations

    28

    h-index

  4. HT
    Hidenori Toyoda

    Ogaki Municipal Hospital, Japan

    32 publications · 1.7K citations

    25

    h-index

  5. TK
    Takashi Kumada

    Ogaki Municipal Hospital, Japan

    33 publications · 1.7K citations

    25

    h-index

1–5 of 5.6K

Venues

  1. Journal of Clinical Oncology

    73 publications · 5.6K citations

    31

    h-index

  2. Liver Cancer

    26 publications · 1.4K citations

    22

    h-index

  3. Cancers

    29 publications · 1.4K citations

    20

    h-index

  4. Frontiers in Oncology

    33 publications · 1.2K citations

    20

    h-index

  5. Hepatology Research

    18 publications · 667 citations

    16

    h-index

1–5